EQ News and Press, Equillium Inc. From 05/09/24

$32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients, representing the first of two data sets that will trigger Ono Pharmaceutical’s optio...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Positive EBITDA and quarterly revenue increased by 19% TORONTO, ON / ACCESSWIRE / April 15, 2024 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data driven software and solutions, announced its financial results today for the fourth quarter and the year ended Decembe...

2024-04-15 12:11:02 ET Bets against energy stocks were higher at the end of March. Average short interest across energy stocks in the S&P 500 index rose 14 basis points to 2.56% of shares floating at the end of the month from February end.... Read the full article on Seeking Alpha...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement awa...

Topline data delivered to Ono Pharmaceutical, representing the first of two data sets that will trigger Ono’s option exercise decision for itolizumab Itolizumab continues to show clinically meaningful response in highly proteinuric subjects More than 80% of subjects achieve...

2024-03-26 12:55:48 ET More on Mid-day movers & stocks. Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Check-Cap jumps on Nobul AI business combination Veritone Non-GAAP EPS of -$0.16 in-line, revenue of $34.2M...

2024-03-25 18:00:44 ET More on Equillium Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Equillium Read the full article on Seeking Alpha For further details see: Equillium GAAP EPS of -$0.07, revenue of $9.2M

$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2 2024 Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus nephr...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Mic...